Achillion discontinuing PNH monotherapy

Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) said it will discontinue development of ACH-4471 as oral monotherapy treatment of paroxysmal nocturnal hemoglobinuria in favor of an earlier stage compound.

The decision is a delay for Achillion as it attempts to offer an alternative to Soliris eculizumab from Alexion Inc. (NASDAQ:ALXN)...